Leigh Matthew Marsh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leigh Matthew Marsh has a total of 454 co-authors. Here are the top co-authors by number of shared publications:
- Grazyna Kwapiszewska
Otto Loewi Research Center, Lung Research Cluster, Medical University of Graz, Graz, Austria
48 shared publications Andrea Olschewski
Ludwig Boltzmann Institute for Lung Vascular Research
27 shared publications- Malgorzata Wygrecka
Department of Biochemistry, Universities of Giessen and Marburg Lung Center, Justus Liebig University of Giessen, Friedrichstrasse 24, 35392 Giessen, Germany
19 shared publications - Horst Olschewski
Faculty of Medicine, Sigmund Freud Private University, 1020 Vienna, Austria
18 shared publications Walter Klepetko
Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Austria
17 shared publications- Werner Seeger
Department of Internal Medicine, Universities of Giessen and Marburg Lung Center (UGMLC) Member of the German Center for Lung Research (DZL) Giessen Germany
17 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1)
Spatial transcriptomics reveals compartment-specific cytotoxic T cell crosstalk with AT2 and goblet cells in advanced COPD
Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation and structural remodelling across different anatomical structures of the lung, including airways, parenchyma, and pulmonary vessels. However, compartment specific changes in immune cell composition and their communications with underlying structural cells remains incompletely defined. Methods: Our study sought to assess the spatially resolved cellular organization of healthy and advanced end-stage COPD lungs using 10X Visium spatial transcriptomics. Non-negative matrix factorization was applied to identify transcriptional programs within spatially distinct areas. Data was validated through an integrative multi-modal approach, including flow cytometry, multiplex immunofluorescence, open access GeoMx Nanostring spatial transcriptomics and scRNA-seq datasets, and proof of concept in vitro co-culture experiments. Results: Spatial mapping of advanced COPD lungs revealed compartment-specific immune and tissue remodelling programs. In the COPD parenchyma, molecular and immune signatures delineated macrophage-rich, remodelling–stress, and humoral B cell immune niches. Airway niches shifted from club cell/innate immunity in controls to goblet cell/adaptive immunity in COPD. Notably cytotoxic T cells colocalised with alveolar type 2 cells within the parenchymal remodelling–stress niche and goblet cells in COPD airways; predicted ligand–receptor interactions implicated these T cells in parenchymal cytotoxic injury and mucus-associated airway remodelling. Conclusions: Our findings delineate compartment-specific cellular microenvironments and interaction networks that may orchestrate tissue remodelling in COPD. This work advances our understanding of immune-driven pathogenesis and pinpoints the cytotoxic T-cell axis as a candidate for targeted therapeutic strategies.
- 25 June 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1)
Open AccessSpatial transcriptomics reveals compartment-specific cytotoxic T cell crosstalk with AT2 and goblet cells in advanced COPD
Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation and structural remodelling across different anatomical structures of the lung, including airways, parenchyma, and pulmonary vessels. However, compartment specific changes in immune cell composition and their communications with underlying structural cells remains incompletely defined. Methods: Our study sought to assess the spatially resolved cellular organization of healthy and advanced end-stage COPD lungs using 10X Visium spatial transcriptomics. Non-negative matrix factorization was applied to identify transcriptional programs within spatially distinct areas. Data was validated through an integrative multi-modal approach, including flow cytometry, multiplex immunofluorescence, open access GeoMx Nanostring spatial transcriptomics and scRNA-seq datasets, and proof of concept in vitro co-culture experiments. Results: Spatial mapping of advanced COPD lungs revealed compartment-specific immune and tissue remodelling programs. In the COPD parenchyma, molecular and immune signatures delineated macrophage-rich, remodelling–stress, and humoral B cell immune niches. Airway niches shifted from club cell/innate immunity in controls to goblet cell/adaptive immunity in COPD. Notably cytotoxic T cells colocalised with alveolar type 2 cells within the parenchymal remodelling–stress niche and goblet cells in COPD airways; predicted ligand–receptor interactions implicated these T cells in parenchymal cytotoxic injury and mucus-associated airway remodelling. Conclusions: Our findings delineate compartment-specific cellular microenvironments and interaction networks that may orchestrate tissue remodelling in COPD. This work advances our understanding of immune-driven pathogenesis and pinpoints the cytotoxic T-cell axis as a candidate for targeted therapeutic strategies.
- Open Access
- 1 June 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Enhanced fatty acid availability rewires fibroblasts metabolism and decreases collagen deposition in lung fibrosis
Pulmonary fibrosis is characterized by irreversible remodeling of the lung parenchyma, which leads to a progressive deterioration in lung function. Pro-fibrotic fibroblasts contribute to uncontrolled extracellular matrix deposition and progression of fibrosis. Emerging evidence implicates metabolic dysregulation - particularly enhanced glycolysis and impaired fatty acid metabolism - in the pathogenesis of pulmonary fibrosis. Here, we investigated whether modulating fatty acid metabolism could counteract fibroblast-driven fibrosis in experimental models. Treatment with pharmacological agents (metformin, rosiglitazone), or genetic ablation of the LPL inhibitory protein, angiopoietin like 4, markedly reduced lung fibrosis and ECM production in bleomycin-induced lung fibrosis mouse model. Similarly, in vitro, provision of albumin-bound fatty acids (FA) in the growth medium reduced TGFβ1-induced collagen production in lung fibroblasts. Mechanistically, excess fatty acid reduced glycolysis, while enhancing mitochondrial function and overall metabolic activity in TGFβ1-treated fibroblasts. This metabolic shift, but not the collagen reduction, was driven by increased fatty acid oxidation via CPT1, as confirmed by the use of the CPT1 inhibitor etomoxir. Importantly, in vivo metabolic interventions downregulated preferentially PDGFRα protein level, while in vitro provision of albumin-bound FA reduced both the amount of collagen produced by αSMA-positive cells and the amount of PDGFRα-positive cells, suggesting a dual role of FA on both pro-fibrotic fibroblasts. Collectively, our findings identify fatty acid oxidation as a potent metabolic checkpoint in fibrotic fibroblasts and support FA availability as a promising strategy to limit lung fibrosis progression.
- 1 June 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessEnhanced fatty acid availability rewires fibroblasts metabolism and decreases collagen deposition in lung fibrosis
Pulmonary fibrosis is characterized by irreversible remodeling of the lung parenchyma, which leads to a progressive deterioration in lung function. Pro-fibrotic fibroblasts contribute to uncontrolled extracellular matrix deposition and progression of fibrosis. Emerging evidence implicates metabolic dysregulation - particularly enhanced glycolysis and impaired fatty acid metabolism - in the pathogenesis of pulmonary fibrosis. Here, we investigated whether modulating fatty acid metabolism could counteract fibroblast-driven fibrosis in experimental models. Treatment with pharmacological agents (metformin, rosiglitazone), or genetic ablation of the LPL inhibitory protein, angiopoietin like 4, markedly reduced lung fibrosis and ECM production in bleomycin-induced lung fibrosis mouse model. Similarly, in vitro, provision of albumin-bound fatty acids (FA) in the growth medium reduced TGFβ1-induced collagen production in lung fibroblasts. Mechanistically, excess fatty acid reduced glycolysis, while enhancing mitochondrial function and overall metabolic activity in TGFβ1-treated fibroblasts. This metabolic shift, but not the collagen reduction, was driven by increased fatty acid oxidation via CPT1, as confirmed by the use of the CPT1 inhibitor etomoxir. Importantly, in vivo metabolic interventions downregulated preferentially PDGFRα protein level, while in vitro provision of albumin-bound FA reduced both the amount of collagen produced by αSMA-positive cells and the amount of PDGFRα-positive cells, suggesting a dual role of FA on both pro-fibrotic fibroblasts. Collectively, our findings identify fatty acid oxidation as a potent metabolic checkpoint in fibrotic fibroblasts and support FA availability as a promising strategy to limit lung fibrosis progression.
- Open Access
- 11 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Transcriptional landscape of pulmonary artery endothelium reveals subpopulation- and disease-specific remodeling signatures
The physiological state of endothelial cells (ECs) is a central determinant of organ health. Distinct endothelial phenotypes and transcriptional programs are linked to vessel size and anatomical location, but it remains unclear how this intrinsic heterogeneity is organized within a particular niche. We performed compartment-specific single-cell profiling of human pulmonary artery (PA) ECs from healthy donors and from patients with two clinically divergent forms of pulmonary hypertension (PH): pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with pulmonary fibrosis (PH-PF). We identified and localized three major EC subsets in healthy and remodeled PAs termed immuno-, vascular tone- and vascular plasticity modulatory, reflecting their enrichment for distinct biological processes. Expression signatures defining each subset were shared with other arterial beds, including the aorta and coronary arteries, and murine PA. Both PAH and PH-PF altered PAEC subset compositions, with increased immunomodulatory and decreased vascular plasticity modulatory PAECs. PH-PF PAECs were generally defined by dysregulated angiogenesis and antigen presentation, whereas PAH PAECs exhibited lipid metabolic dysfunction and enhanced vasoregulatory signaling. By uncovering endothelial heterogeneity and pathology-specific transcriptional programs in PAs, this study underscores the need of disease-specific therapeutic targeting.
- 11 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessTranscriptional landscape of pulmonary artery endothelium reveals subpopulation- and disease-specific remodeling signatures
The physiological state of endothelial cells (ECs) is a central determinant of organ health. Distinct endothelial phenotypes and transcriptional programs are linked to vessel size and anatomical location, but it remains unclear how this intrinsic heterogeneity is organized within a particular niche. We performed compartment-specific single-cell profiling of human pulmonary artery (PA) ECs from healthy donors and from patients with two clinically divergent forms of pulmonary hypertension (PH): pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with pulmonary fibrosis (PH-PF). We identified and localized three major EC subsets in healthy and remodeled PAs termed immuno-, vascular tone- and vascular plasticity modulatory, reflecting their enrichment for distinct biological processes. Expression signatures defining each subset were shared with other arterial beds, including the aorta and coronary arteries, and murine PA. Both PAH and PH-PF altered PAEC subset compositions, with increased immunomodulatory and decreased vascular plasticity modulatory PAECs. PH-PF PAECs were generally defined by dysregulated angiogenesis and antigen presentation, whereas PAH PAECs exhibited lipid metabolic dysfunction and enhanced vasoregulatory signaling. By uncovering endothelial heterogeneity and pathology-specific transcriptional programs in PAs, this study underscores the need of disease-specific therapeutic targeting.
- Open Access
- 29 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (44)
Metabolic adaptation of glucose-deprived macrophages involves partial gluconeogenesis
Macrophages are recruited to sites of infection contributing to the killing of bacteria, but also to malignant tumors, where they promote angiogenesis and suppress antitumor immune responses. The metabolic microenvironment in tumors is frequently depleted of important nutrients such as glucose. Here, we investigated metabolic adaptation strategies of macrophages to glucose deprivation using stable isotopic tracing. Lactate production was decreased, potentially indicating a reduction of glycolysis. In contrast, the contribution of glutamine to the tricarboxylic acid cycle via α-ketoglutarate and reductive carboxylation were increased. Moreover, gluconeogenesis, the reverse pathway of glycolysis, was activated in glucose-deprived macrophages, proceeding partially to the generation of glycolytic intermediates and glycerol-3-phosphate. The partial gluconeogenesis pathway was abrogated in human and murine macrophages lacking the initial gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PCK2, mitochondrial isoform). Partial gluconeogenesis was higher in anti-inflammatory, interleukin-4-stimulated compared to proinflammatory, interferon-γ/lipopolysaccharide-stimulated macrophages. Single-cell analysis and immunostaining revealed expression of PCK2 in macrophages from both lung cancer and normal lung. Low glucose conditions only partially modulated macrophage phenotypes, leading to reduced CD80 surface marker levels in proinflammatory, and enhanced vascular endothelial growth factor expression in anti-inflammatory macrophages. Our study reveals partial gluconeogenesis in glucose-deprived macrophages and shows that this versatile type of immune cells exhibits remarkable metabolic flexibility.
- 29 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (44)
Open AccessMetabolic adaptation of glucose-deprived macrophages involves partial gluconeogenesis
Macrophages are recruited to sites of infection contributing to the killing of bacteria, but also to malignant tumors, where they promote angiogenesis and suppress antitumor immune responses. The metabolic microenvironment in tumors is frequently depleted of important nutrients such as glucose. Here, we investigated metabolic adaptation strategies of macrophages to glucose deprivation using stable isotopic tracing. Lactate production was decreased, potentially indicating a reduction of glycolysis. In contrast, the contribution of glutamine to the tricarboxylic acid cycle via α-ketoglutarate and reductive carboxylation were increased. Moreover, gluconeogenesis, the reverse pathway of glycolysis, was activated in glucose-deprived macrophages, proceeding partially to the generation of glycolytic intermediates and glycerol-3-phosphate. The partial gluconeogenesis pathway was abrogated in human and murine macrophages lacking the initial gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PCK2, mitochondrial isoform). Partial gluconeogenesis was higher in anti-inflammatory, interleukin-4-stimulated compared to proinflammatory, interferon-γ/lipopolysaccharide-stimulated macrophages. Single-cell analysis and immunostaining revealed expression of PCK2 in macrophages from both lung cancer and normal lung. Low glucose conditions only partially modulated macrophage phenotypes, leading to reduced CD80 surface marker levels in proinflammatory, and enhanced vascular endothelial growth factor expression in anti-inflammatory macrophages. Our study reveals partial gluconeogenesis in glucose-deprived macrophages and shows that this versatile type of immune cells exhibits remarkable metabolic flexibility.
- 1 September 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 73 (3) , 343-352
The Acrolein–Lipopolysaccharide Mouse Model for Frequent Exacerbations in Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a severe progressive lung disease, often caused by prolonged exposure to cigarette smoke and environmental factors. Preclinical COPD research predominately relies on chronic smoke or elastase animal models, each with their own advantages and limitations, such as limited pathophysiological insights or long treatment times. Here we describe a novel and time-efficient mouse model of COPD based on bacterial LPS and the reactive aldehyde acrolein (Acro). Mice were treated once per week for 4 weeks with a combination of both LPS and Acro. Histological, inflammatory, and metabolomic alterations were analyzed by histological quantification, multicolor flow cytometry, and nuclear magnetic resonance. Acro/LPS treatment induced moderate airspace enlargement and bronchial remodeling. These structural changes were associated with a distinct inflammatory profile marked by an increase in macrophages and T-helper cells, as well as increased cytokines, including CXCL11, IL-17a, and TNF-α. Strong inflammation, consisting of T-helper and B cells, was detected in the perivascular and peribronchial spaces and increased macrophages in the alveolar regions. In addition, intervention with the steroid dexamethasone induced a strong reduction in T cells and macrophages and partially ameliorated histological alterations. Furthermore, we could detect alterations in the metabolome of serum and tissue, including an increase in COPD-associated metabolites like trimethylamine N-oxide, as well as a misbalance in energy-related metabolites and several amino acids. In summary, we can describe a practical, representative, and time-efficient mouse model of COPD, with the potential to study the immunological and pathophysiological development of the disease.
- 1 September 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 73 (3) , 343-352
The Acrolein–Lipopolysaccharide Mouse Model for Frequent Exacerbations in Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a severe progressive lung disease, often caused by prolonged exposure to cigarette smoke and environmental factors. Preclinical COPD research predominately relies on chronic smoke or elastase animal models, each with their own advantages and limitations, such as limited pathophysiological insights or long treatment times. Here we describe a novel and time-efficient mouse model of COPD based on bacterial LPS and the reactive aldehyde acrolein (Acro). Mice were treated once per week for 4 weeks with a combination of both LPS and Acro. Histological, inflammatory, and metabolomic alterations were analyzed by histological quantification, multicolor flow cytometry, and nuclear magnetic resonance. Acro/LPS treatment induced moderate airspace enlargement and bronchial remodeling. These structural changes were associated with a distinct inflammatory profile marked by an increase in macrophages and T-helper cells, as well as increased cytokines, including CXCL11, IL-17a, and TNF-α. Strong inflammation, consisting of T-helper and B cells, was detected in the perivascular and peribronchial spaces and increased macrophages in the alveolar regions. In addition, intervention with the steroid dexamethasone induced a strong reduction in T cells and macrophages and partially ameliorated histological alterations. Furthermore, we could detect alterations in the metabolome of serum and tissue, including an increase in COPD-associated metabolites like trimethylamine N-oxide, as well as a misbalance in energy-related metabolites and several amino acids. In summary, we can describe a practical, representative, and time-efficient mouse model of COPD, with the potential to study the immunological and pathophysiological development of the disease.
- Open Access
- 10 April 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Adventitial fibroblasts direct smooth muscle cell-state transition in pulmonary vascular disease
Background: Pulmonary vascular remodeling is a progressive pathological process characterized by functional alterations within pulmonary artery smooth muscle cells (PASMCs) and adventitial fibroblasts (PAAFs). Mechanisms driving the transition to a diseased phenotype remain elusive.Methods: We combined transcriptomic and proteomic profiling with phenotypic characterization of source-matched cells from healthy controls and individuals with idiopathic pulmonary arterial hypertension (IPAH). Bidirectional cellular crosstalk was examined using direct and indirect co-culture models, and phenotypic responses were assessed via transcriptome analysis.Results: PASMC and PAAF undergo distinct phenotypic shifts during pulmonary vascular remodeling, with limited shared features, such as reduced mitochondrial content and hyperpolarization. IPAH-PASMC exhibit increased glycosaminoglycan production and downregulation of contractile machinery, while IPAH-PAAF display a hyperproliferative phenotype. We identified alterations in extracellular matrix components, including laminin and collagen, alongside pentraxin-3 and hepatocyte growth factor, as potential regulators of PASMC phenotypic transitions mediated by PAAF.Conclusions: While PASMCs and PAAFs retain their core cellular identities, they acquire distinct disease-associated states. These findings provide new insights into the dynamic interplay of pulmonary vascular mesenchymal cells in disease pathogenesis.Funding: This work was supported by Cardio-Pulmonary Institute EXC 2026 390649896 (GK) and Austrian Science Fund (FWF) grant I 4651-B (SC).
- 10 April 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessAdventitial fibroblasts direct smooth muscle cell-state transition in pulmonary vascular disease
Background: Pulmonary vascular remodeling is a progressive pathological process characterized by functional alterations within pulmonary artery smooth muscle cells (PASMCs) and adventitial fibroblasts (PAAFs). Mechanisms driving the transition to a diseased phenotype remain elusive.Methods: We combined transcriptomic and proteomic profiling with phenotypic characterization of source-matched cells from healthy controls and individuals with idiopathic pulmonary arterial hypertension (IPAH). Bidirectional cellular crosstalk was examined using direct and indirect co-culture models, and phenotypic responses were assessed via transcriptome analysis.Results: PASMC and PAAF undergo distinct phenotypic shifts during pulmonary vascular remodeling, with limited shared features, such as reduced mitochondrial content and hyperpolarization. IPAH-PASMC exhibit increased glycosaminoglycan production and downregulation of contractile machinery, while IPAH-PAAF display a hyperproliferative phenotype. We identified alterations in extracellular matrix components, including laminin and collagen, alongside pentraxin-3 and hepatocyte growth factor, as potential regulators of PASMC phenotypic transitions mediated by PAAF.Conclusions: While PASMCs and PAAFs retain their core cellular identities, they acquire distinct disease-associated states. These findings provide new insights into the dynamic interplay of pulmonary vascular mesenchymal cells in disease pathogenesis.Funding: This work was supported by Cardio-Pulmonary Institute EXC 2026 390649896 (GK) and Austrian Science Fund (FWF) grant I 4651-B (SC).
- 1 March 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 328 (3) , L413-L429
Pulmonary vascular remodeling in Fra-2 transgenic mice is driven by type 2 inflammation and accompanied by pulmonary vascular hyperresponsiveness
In patients suffering from systemic sclerosis (SSc), pulmonary arterial hypertension (PAH) is a life-threatening complication linked to immune dysregulation. Preclinical analyses in Fos-related antigen-2 (Fra-2) transgenic (TG) mice, a model of SSc-PAH, identify type 2 inflammation as a key driver of vascular remodeling. Anti-inflammatory treatment targeting type 2 inflammation via IL-13 neutralizing antibodies improved pulmonary vascular remodeling. Thus, type 2-specific anti-inflammatory treatment may be a promising therapeutic approach in SSc-PAH.
- 1 March 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 328 (3) , L413-L429
Pulmonary vascular remodeling in Fra-2 transgenic mice is driven by type 2 inflammation and accompanied by pulmonary vascular hyperresponsiveness
In patients suffering from systemic sclerosis (SSc), pulmonary arterial hypertension (PAH) is a life-threatening complication linked to immune dysregulation. Preclinical analyses in Fos-related antigen-2 (Fra-2) transgenic (TG) mice, a model of SSc-PAH, identify type 2 inflammation as a key driver of vascular remodeling. Anti-inflammatory treatment targeting type 2 inflammation via IL-13 neutralizing antibodies improved pulmonary vascular remodeling. Thus, type 2-specific anti-inflammatory treatment may be a promising therapeutic approach in SSc-PAH.
- Open Access
- 28 February 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Adventitial fibroblasts direct smooth muscle cell-state transition in pulmonary vascular disease
Summary Pulmonary vascular remodeling is a progressive pathological process characterized by functional alterations within pulmonary artery smooth muscle cells (PASMC) and adventitial fibroblasts (PAAF). Mechanisms driving the transition to a diseased phenotype remain elusive. Utilizing a combination of transcriptomic and proteomic profiling, along with phenotyping of source-matched cells from healthy controls and individuals with idiopathic pulmonary arterial hypertension (IPAH), our investigation uncovered that while PASMC and PAAF retained their original cellular identities, they acquired distinct disease-associated states. Though both cell types exhibited reduced mitochondrial content and hyperpolarization, IPAH-PASMC displayed heightened glycosaminoglycan production and downregulation of contractile machinery, contrasting a hyperproliferative phenotype of IPAH-PAAF. We investigated the involvement of cellular crosstalk in regulating cell state dynamics and identified pentraxin-3 and hepatocyte growth factor as potential modulators of PASMC phenotypic transition orchestrated by PAAF. Our findings contribute to a deeper understanding of pulmonary vascular mesenchyme dynamics in disease pathogenesis.
- 28 February 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessAdventitial fibroblasts direct smooth muscle cell-state transition in pulmonary vascular disease
Summary Pulmonary vascular remodeling is a progressive pathological process characterized by functional alterations within pulmonary artery smooth muscle cells (PASMC) and adventitial fibroblasts (PAAF). Mechanisms driving the transition to a diseased phenotype remain elusive. Utilizing a combination of transcriptomic and proteomic profiling, along with phenotyping of source-matched cells from healthy controls and individuals with idiopathic pulmonary arterial hypertension (IPAH), our investigation uncovered that while PASMC and PAAF retained their original cellular identities, they acquired distinct disease-associated states. Though both cell types exhibited reduced mitochondrial content and hyperpolarization, IPAH-PASMC displayed heightened glycosaminoglycan production and downregulation of contractile machinery, contrasting a hyperproliferative phenotype of IPAH-PAAF. We investigated the involvement of cellular crosstalk in regulating cell state dynamics and identified pentraxin-3 and hepatocyte growth factor as potential modulators of PASMC phenotypic transition orchestrated by PAAF. Our findings contribute to a deeper understanding of pulmonary vascular mesenchyme dynamics in disease pathogenesis.
- Open Access
Connectivity Map and perturbation-based sensitivity analysis identifies MEK inhibitors as senolytics in human lung fibroblasts
Recently, the elimination of the disease-associated accumulation of senescent cells using senolytics has been shown to exert health benefits in animal studies. However, due to the heterogeneity of cell senescence and its unrecognized master regulators, drug development faces a complexity that must be handled. Bioinformatic elucidation of genes and pathways involved in senolysis and prediction of senolytic activity of compounds can cut costs and facilitate faster achievements in the field. In the present investigation, after obtaining the consensus gene signature of senescent fibroblasts of lung origin and deriving its anti-apoptotic module, we utilized Connectivity Map (CMap) alongside small molecule and genetic perturbation sensitivity data in cancer cell lines to identify drugs and genetic interventions that might induce apoptosis or sensitize senescent cells to apoptosis. Through bioinformatic evaluations, we speculate that activation of early stages of autophagy which contributes to the formation of autophagosomes, concurrent with the activation of waste protein concealment system by the mean of p62 and chaperoning system alongside an increase in JUNB gene expression can secure the survival of the senescent cells even when homeostasis of different cellular processes is disrupted. Moreover, our bioinformatic evaluation proposed selumetinib, a MEK inhibitor, as a senolytic against senescent lung fibroblasts. The senolytic activity of a variety of MEK inhibitors in senescent lung fibroblasts was confirmed using human lung fibroblasts in vitro.
Open AccessConnectivity Map and perturbation-based sensitivity analysis identifies MEK inhibitors as senolytics in human lung fibroblasts
Recently, the elimination of the disease-associated accumulation of senescent cells using senolytics has been shown to exert health benefits in animal studies. However, due to the heterogeneity of cell senescence and its unrecognized master regulators, drug development faces a complexity that must be handled. Bioinformatic elucidation of genes and pathways involved in senolysis and prediction of senolytic activity of compounds can cut costs and facilitate faster achievements in the field. In the present investigation, after obtaining the consensus gene signature of senescent fibroblasts of lung origin and deriving its anti-apoptotic module, we utilized Connectivity Map (CMap) alongside small molecule and genetic perturbation sensitivity data in cancer cell lines to identify drugs and genetic interventions that might induce apoptosis or sensitize senescent cells to apoptosis. Through bioinformatic evaluations, we speculate that activation of early stages of autophagy which contributes to the formation of autophagosomes, concurrent with the activation of waste protein concealment system by the mean of p62 and chaperoning system alongside an increase in JUNB gene expression can secure the survival of the senescent cells even when homeostasis of different cellular processes is disrupted. Moreover, our bioinformatic evaluation proposed selumetinib, a MEK inhibitor, as a senolytic against senescent lung fibroblasts. The senolytic activity of a variety of MEK inhibitors in senescent lung fibroblasts was confirmed using human lung fibroblasts in vitro.